Founded in 2005 as a result of interdisciplinary research at the Karolinska Institute in Stockholm, Sweden, Vironova has quickly established a following of global customers working in highly-regulated and quality-demanding industries such as vaccine development, the pharmaceutical industry and material science.
By combining expertise in electron microscopy, virology, mathematics and image analysis, Vironova has developed a unique offering of services, hardware and software products. Today it has GLP-certified cell and virus facilities in Sweden that include equipment for advanced electron microscopy, image analysis, nano-characterization and viral clearance testing.
Vironova strives to protect all technology and products developed. Patent applications are submitted in all relevant markets for new technology and technology improvements.
The technology is protected by patents and patent applications for three complementing image analysis methods, and covers the most important application areas in biological quality control.
Vironova has a culture of responsibility, drive and cost consciousness, which allows the company to innovate and market products and services at a high level.
Mr. Homman has a M.Sc. in Chemistry and B.Sc in biology from Uppsala University in 1998. Mohammed has been the driving force behind the development of the virus analysis technique and VN-180. Mohammed has received several national and international awards in recognition of his entrepreneurship and innovative research achievements. In 2003 Mohammed was chosen as one of the “Leaders of Tomorrow” by the Academy of Achievement, USA.
Niklas brings extensive experience from rapidly growing listed and unlisted companies from various industries where he has gained a vast experience in introducing companies to a commercial phase as well as the capital market.
Worked at Vironova since 2015.
Dr. Ida-Maria SintornCTO
Dr. Ida-Maria Sintorn
Born in 1976, has worked at Vironova since 2007. Ida-Maria is associate professor (docent) in computerized image processing at Uppsala University, holds a Ph.D. in image analysis from Swedish University of Agricultural Sciences as well as a M.Sc. in molecular biotechnology engineering from Uppsala University. Ida-Maria has a solid background in theoretical and applied image analysis and pattern recognition. She has combined an academic and industrial career and today holds both a position as associate professor at Uppsala University and as CTO of Vironova.
Göran NilssonBusiness Development Director
Göran holds a M.Sc in Management of information from Chalmers University and a M.Sc in Economics from the University of Gothenburg. Göran has worked as a management consultant in strategy and operations for McKinsey & Company where he served clients in multiple industries, including several global pharmaceutical companies.
Ulf DanielssonSales & Marketing Director
Ulf brings more than 30 years’ experience of sales and marketing in the life sciences industry to Vironova. Prior to joining the company he has held positions as Sales Manager and Sales Director at Pharmadule, Pall Filtration and Pharmacia Biotech (Ge Healthcare Life Sciences). He holds a B.Sc in chemistry.
Dr. Josefina NilssonDirector of BU, EM services
Dr. Josefina Nilsson
Josefina holds a Ph.D. in biophysics and structural biology from the Karolinska Institute and a M.Sc. in chemistry from Uppsala University. Josefina has unique expertise in structural analysis of viruses and nanoparticles, electron microscopy and its industrial applications, gained from the PhD program “Biotechnology with an industrial focus” and from her work at Vironova as head of virology and head of sales.
Dr. Carina PèrezDirector of BU, Biosafety
Dr. Carina Pèrez
Born in 1978, has worked at Vironova since 2013. Carina holds a Ph.D. in Medical Science from Karolinska Institutet and a M.Sc. in molecular cell biology from Södertörn University in Stockholm. Carina has a solid academic background in immunology, virology and vaccinology. Her research with focus on HIV has given her experience and skills in biosecurity risk assessment and sterile working techniques. Carina also has management, leadership and entrepreneur skills from founding and running a non-profit organization.
Ulrika LedmyrHR Director
Ulrika holds a BS.c in Human Resources and Labour Law from Stockholms University and also one year Psychology studies at the same University. Ulrika has a long experience as Head of HR in different companies such as the service industry, IT-sector, Academy, public services and law firm. Ulrika’s speciality is structure, processes and building an HR-plattform. Ulrika works as a HR Director at Vironova since August 2016.
Anders MiltonChairman of the Board
Born 1947. Chairman of the Board since 2008.
B.Sc., M.D., Ph.D. Milton is the president of ERNA, a member of the government appointed Catastrophe Commission and a consultant within the health care sector. Dr. Milton is also on the board of publicly traded Q-Med AB. Dr. Milton has a long history of elected positions as well as government appointed positions. He has previously been both CEO and Secretary General of the Swedish Medical Association, chairman of the Council of the World Medical Association, Chairman of the Swedish Red Cross and Chairman of the Swedish Confederation of Professional Associations (SACO), as well as Government appointed co-ordinator of psychiatric services in Sweden and government appointed chairman of a committee on HIV/AIDS.
Ove MattssonMember of the board
Born 1940. Member of the board since 2014.
Ph.D. and associate professor in organic chemistry from Stockholm University. Dr. Mattsson served as President and CEO of Nobel Industries AB between 1991 and 1994, CEO of Akzo Nobel Coatings between 1994 and 2000, and President of Casco Nobel AB between 1978 and 1991. Chairman of the board at Biotage AB, Fabryo Corporation SRL, Nico AB, Nico Real Estate AB and Nico Export AB, and member of the board at Ecolean AB.
Ulf SätherMember of the board
Born 1959. Member of the board since 2014.
M.Sc. from Stockholm School of Economics. Ulf has 25 years of experience in the pharmaceutical industry, mostly in international and global roles. Most recently 10 years as President Europe in AstraZeneca, based in Brussels, followed by the role as Global Marketing Director at the company headquarters in London. Earlier in his career he also held sales and marketing roles in the US. Board member in RISE (Research Institutes of Sweden), a government body with 2500 employees doing front line research in collaboration with industry, N-side, Leuwen Belgium, a consulting firm in mathematical analysis, Nobelux, a trade org to support trade between Sweden and Belux. Former member of the board at AB Blåklader (working wear) and Chairman in the AZ Germany Supervisory Board. Industrial Advisor at EQT.
Alf SolleviMember of the board
Born 1951. Member of the Board since 2014.
Professor in anesthesiology and intensive care since 1999 at the Department of Clinical Science, Intervention and Technology at the Karolinska Institute. Dr. Sollevi received his medical degree in 1976 and became a licensed physician in 1978. He received his PhD in 1981. After two years as Associate Professor of Pharmacology, he became a docent in anesthesiology and intensive care in 1986. During a long period, from 1982 to 2008, has Dr. Sollevi lead a research group that conducted basic studies as well as clinical examinations regarding effects and clinical applicability of the endogenous substance adenosine.
Mats PerssonMember of the board
Born 1948. Member of the board since 2014.
M.Sc. from Stockholm School of Economics, MBA from University of Berkeley, California. Mats Persson has an extensive experience as CEO at several Swedish companies including AGA Gas, Thermiaverken, Candor and Interspiro, with a focus on implementing major organizational changes and increasing profitability. During 1996-2012 Mats Persson served as main shareholder in Neuman and Nydahl, offering qualified counselling, leadership development and recruitment at managerial level to leading companies in Sweden, including Incentive, Skanska, Swedbank, Boliden, Loomis, Nynäs and Pharmacia. Mats Persson has over 20 years of experience in board work, and is currently board member at Prolight Diagnostics, Newfour, QBNK (Aktietorget) and Vironova.
Mohammed HommanFounder & CEO
Born 1974. Founder and CEO of Vironova, member of the Board since 2006.
Mohammed Homman has a M.Sc. in Chemistry and B.Sc in biology from Uppsala University in 1998. He has received several national and international awards in recognition of his entrepreneurship and innovative research achievements. In 2003 Mohammed Homman was chosen as one of the “Leaders of Tomorrow” by the Academy of Achievement, USA.
Peter ThurellDeputy member
Born 1946. Deputy member since 2014.
Chairman and CEO of international pharmaceutical company Item Development since 1989, following a period of positions as controller / trouble shooter and/or president in several medium size subsidiaries of Swedish investment group Navigator.Trained in the Royal Swedish Navy (captain), at the University of Lund (law), the University of Stockholm (tax law), the Stockholm School of Economics (BSc in economics and business administration) and IMD in Lausanne (international executive program).
Maria HommanDeputy member
Born 1974. Deputy member since 2011.
Ph.D. Maria Homman is Laboratory Manager for Adhesives Development Team in Nacka, AkzoNobel. Dr. Maria Homman was previously Member of the Board (2006-2011) and Chairman of the Board (2006-2008) .
Dr. Jan BergmanScientific advisor
Dr. Jan Bergman
Jan Bergman received his PhD in 1971 from the Royal Institute of Technology in Stockholm, Sweden. He wrote his thesis about the studies of indole derivatives, aromatic heterocyclic organic compounds that are widely distributed components in nature. He continued to focus his research on the studies of complex organic molecules and their application in drug design as biologically active compounds. He was appointed professor in 1990 at Södertörn University College and Karolinska Institute where he supervised over 30 PhD- and 20 post-doctoral students publishing more than 300 scientific articles in the organic chemistry field. He has also contributed as an author/co-author to several organic chemistry books. He has additional academic experience as a chair/editorial board member of numerous international organic chemistry associations. He has been appointed to contribute in peer reviews, professorship evaluations and as a chemistry expert advisor in the court of appeals. He is the inventor of over 10 patent applications for molecules against bacteria, herpes virus, influenza virus, Multiple Sclerosis, Rheumatoid Arthritis and a chemical process called thionation. Since 2005, Emeritus Professor Jan Bergman, has played a significant role in Vironova’s goal to provide drugs that are effective against infectious diseases such as herpes, influenza as well as a european patent-approved chemical process for the thionation of compounds used in pharmaceuticals.
Dr. Jan-Olov StrömbergScientific advisor
Dr. Jan-Olov Strömberg
Jan Olov Strömberg received his Fil.Kand degree from Stockholm University, Stockholm, Sweden, in 1969, and his Ph.D degree in mathematics at Upsala College, East Orange, NJ, in 1977. He was an Instructor and Assistant Professor at Princeton University, Princeton, NJ, from 1977 to 1980, Forskarassistent at Stockholm University from 1980 to 1982, and a Professor at University of Tromsø, Sweden, from 1982 to 1998. Since 1998, he has been a Professor of computational harmonic analysis at the Royal Institute of Technology, Stockholm. He has written about 30 publications and conference proceedings, most in harmonic analysis. His construction of an unconditional basis of Hardy spaces is the first known continuous orthonormal wavelet basis. Recently, his mathematical interest has been in applied mathematics.
The Vironova Group consists of four companies:
- Intelligent Virus Imaging Inc. (IVI Inc.) is a fully owned subsidiary in the USA used for certain patent rights.
- Vironova Biosafety AB is a fully owned subsidiary.
- NOW Electronics AB is a fully owned daughter company.
- JOS AB is a fully owned subsidiary.
Share structure, September 30th, 2016
|Share holder||No. of shares, class A||No. of shares, class B||% of capital||% of votes|
|Holmsvanen AB||8 446 665||31,75%||17,24%|
|M Homman AB||2 487 503||2 489 196||18,71%||55,86%|
|Alf Sollevi||4 267 042||16,04%||8,71%|
|Flerie Invest AB||1 000 000||3,76%||2,04%|
|Dyneq AB||973 958||3,66%||1,99%|
|Sanderling Invest AB||670 000||2,52%||1,37%|
|Anders Milton||493 000||1,85%||1,01%|
|Avanza bank||400 797||1,51%||0,82%|
|TK Buss Kisa AB||428 718||1,61%||0,88%|
|Tomas Karlsson||300 000||1,13%||0,61%|
|Others||4 645 126||17,46%||9,47%|
|Total||2 487 503||24 114 502||100,00%||100,00%|
Share capital in Vironova AB at September 30, 2016 amounted to SEK 1,330,100.25 distributed among 2,487,503 Class A shares and 24 114 502 Class B shares, each with a quotient value of SEK 0.05. The total number of shares amounted to 26 602 005. Class A shares carry ten voting rights each, while Class B shares carry one vote. All shares provide equal entitlement to participation in the company and are freely transferable.
Source: Euroclear AB